Press release
Nonalcoholic Steatohepatitis Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies
Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Nonalcoholic Steatohepatitis Treatment Landscape. Click here to read more @ Nonalcoholic Steatohepatitis Pipeline Outlook [https://www.delveinsight.com/sample-request/non-alcoholic-steatohepatitis-nash-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Nonalcoholic Steatohepatitis Pipeline Report
* In March 2025, Zydus Therapeutics Inc . announced a study to Evaluate Efficacy and Safety of Saroglitazar Magnesium in Subjects with Nonalcoholic Steatohepatitis and Fibrosis.
* In March 2025, Novo Nordisk A/S conducted the study will last for about 5 years. Participants will have up to 21 clinic visits and 9 phone calls with the clinical staff during the study. Some of the clinic visits may be spread over more than one day. Participants with other chronic liver diseases cannot take part in this study. Women cannot take part in the study if they are pregnant, breast-feeding or plan to become pregnant during the study period.
* In March 2025, 89Bio Inc, announced the study will assess the efficacy and safety of pegozafermin administered in participants with compensated cirrhosis due to MASH (biopsy-confirmed fibrosis stage F4 MASH [previously known as nonalcoholic steatohepatitis, NASH]).
* DelveInsight's Nonalcoholic Steatohepatitis Pipeline analysis depicts a robust space with 80+ active players working to develop 80+ pipeline treatment therapies.
* DelveInsight's Nonalcoholic Steatohepatitis pipeline report depicts a robust space with 80+ active players working to develop 80+ pipeline therapies for Nonalcoholic Steatohepatitis treatment.
* The leading Nonalcoholic Steatohepatitis Companies such as Guangdong Raynovent Biotech, Dr. Falk Pharma GmbH, Enyo Pharma, Viking Therapeutics, Eli Lilly and Company, Sagimet Biosciences, Terns, Sinew Pharma, Madrigal Pharmaceuticals, Hepion Pharmaceuticals, Poxel SA, Pfizer, CytoDyn, Altimmune, Oramed, Ltd, PharmaKing, Can-Fite Biopharma, Cirius Therapeutics , and others.
* Promising Nonalcoholic Steatohepatitis Therapies such as AZD2693, Saroglitazar Magnesium 4 mg, Semaglutide (SEMA), Cilofexor (CILO)/Firsocostat (FIR), and others.
Discover groundbreaking developments in Nonalcoholic Steatohepatitis therapies! Gain in-depth knowledge of key Nonalcoholic Steatohepatitis clinical trials, emerging drugs, and market opportunities @ Nonalcoholic Steatohepatitis Clinical Trials Assessment [https://www.delveinsight.com/sample-request/non-alcoholic-steatohepatitis-nash-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Nonalcoholic Steatohepatitis Emerging Drugs Profile
* Lanifibranor: Inventiva Pharma
Lanifibranor, Inventiva's lead product candidate, is an orally-available small molecule that acts to induce antifibrotic, anti-inflammatory and beneficial vascular and metabolic changes in the body by activating all three peroxisome proliferator-activated receptor (PPAR) isoforms, which are well-characterized nuclear receptor proteins that regulate gene expression. Lanifibranor is a PPAR agonist that is designed to target all three PPAR isoforms in a moderately potent manner, with a well-balanced activation of PPAR and PPAR, and a partial activation of PPAR. While other PPAR agonists target only one or two PPAR isoforms for activation. The FDA has granted Breakthrough Therapy and Fast Track designation to lanifibranor for the treatment of NASH. Currently, the drug is in Phase III stage of its clinical trial for the treatment of NASH.
* MSDC-0602K: Cirius Therapeutics
MSDC-0602K, a second-generation oral insulin sensitizer, is designed to selectively modulate the mitochondrial pyruvate carrier (MPC) while minimizing direct PPAR-gamma activation. The MPC mediates at the cellular level the effects of over nutrition, a major cause of Nonalcoholic fatty liver disease NAFLD/NASH and Type 2 diabetes. In preclinical studies, modulation of the MPC has been shown to improve insulin sensitivity, lipid metabolism, and inflammation. Currently the drug is in Phase III stage of Clinical trial for the treatment of NASH.
* TERN-501: Terns Pharmaceuticals
TERN-501 is a THR- agonist with high metabolic stability, enhanced liver distribution and greater selectivity for THR- compared to other THR- agonists in development. Agonism of THR- increases fatty acid metabolism via mitochondrial oxidation and affects cholesterol synthesis and metabolism. As a result, THR- stimulation has the ability to reduce hepatic steatosis and improve serum lipid parameters including LDL cholesterol and triglycerides. In vivo NASH studies in a rodent model have demonstrated that low-doses of TERN-501 achieved complete resolution of steatosis and reductions in serum lipids, hepatic inflammation and fibrosis. TERN-501 has high liver distribution and is 23-fold more selective for THR- than for THR- activation in a cell free assay, thereby minimizing the risk of cardiotoxicity and other off-target effects associated with non-selective THR stimulation. Currently, the drug is in Phase II stage of its clinical trial for the treatment of NASH.
* HTD 1801: HighTide Biopharma
The company's lead drug candidate, HTD1801, is a first-in-class new molecular entity (ionic salt of two active moieties). It is a novel orally active ionic salt of berberine and ursodeoxycholic acid, substantially reduced liver fat while improving glycemic control and other cardiometabolic biomarkers in adults with nonalcoholic steatohepatitis (NASH) and type 2 diabetes (T2DM). Currently, it is in Phase II trials for the treatment of primary sclerosing cholangitis (PSC), and nonalcoholic steatohepatitis (NASH).
The Nonalcoholic Steatohepatitis Pipeline report provides insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Nonalcoholic Steatohepatitis with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Nonalcoholic Steatohepatitis Treatment.
* Nonalcoholic Steatohepatitis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Nonalcoholic Steatohepatitis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Nonalcoholic Steatohepatitis market
Stay informed about the Nonalcoholic Steatohepatitis pipeline trends! Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Nonalcoholic Steatohepatitis Unmet Needs [https://www.delveinsight.com/sample-request/non-alcoholic-steatohepatitis-nash-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Nonalcoholic Steatohepatitis Companies
Guangdong Raynovent Biotech, Dr. Falk Pharma GmbH, Enyo Pharma, Viking Therapeutics, Eli Lilly and Company, Sagimet Biosciences, Terns, Sinew Pharma, Madrigal Pharmaceuticals, Hepion Pharmaceuticals, Poxel SA, Pfizer, CytoDyn, Altimmune, Oramed, Ltd, PharmaKing, Can-Fite Biopharma, Cirius Therapeutics, and others.
Nonalcoholic Steatohepatitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration
* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical
Nonalcoholic Steatohepatitis Products have been categorized under various Molecule types such as
* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy
Transform your understanding of the Nonalcoholic Steatohepatitis Pipeline! See the latest progress in drug development and clinical research @ Nonalcoholic Steatohepatitis Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/non-alcoholic-steatohepatitis-nash-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Nonalcoholic Steatohepatitis Pipeline Report
* Coverage- Global
* Nonalcoholic Steatohepatitis Companies- Guangdong Raynovent Biotech, Dr. Falk Pharma GmbH, Enyo Pharma, Viking Therapeutics, Eli Lilly and Company, Sagimet Biosciences, Terns, Sinew Pharma, Madrigal Pharmaceuticals, Hepion Pharmaceuticals, Poxel SA, Pfizer, CytoDyn, Altimmune, Oramed, Ltd, PharmaKing, Can-Fite Biopharma, Cirius Therapeutics , and others.
* Nonalcoholic Steatohepatitis Therapies- AZD2693, Saroglitazar Magnesium 4 mg, Semaglutide (SEMA), Cilofexor (CILO)/Firsocostat (FIR) , and others.
* Nonalcoholic Steatohepatitis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Nonalcoholic Steatohepatitis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Stay Ahead in Oncology Research-Access the Full Nonalcoholic Steatohepatitis Pipeline Analysis Today! @ Nonalcoholic Steatohepatitis Drugs and Companies [https://www.delveinsight.com/sample-request/non-alcoholic-steatohepatitis-nash-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* Nonalcoholic Steatohepatitis: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Nonalcoholic Steatohepatitis- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Lanifibranor: Inventiva Pharma
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* TERN-501: Terns Pharmaceuticals
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* LY3849891: Eli Lilly and Company
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug name : Company name
* Drug profiles in the detailed report.....
* Inactive Products
* Nonalcoholic Steatohepatitis Key Companies
* Nonalcoholic Steatohepatitis Key Products
* Nonalcoholic Steatohepatitis- Unmet Needs
* Nonalcoholic Steatohepatitis- Market Drivers and Barriers
* Nonalcoholic Steatohepatitis- Future Perspectives and Conclusion
* Nonalcoholic Steatohepatitis Analyst Views
* Nonalcoholic Steatohepatitis Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=nonalcoholic-steatohepatitis-clinical-trials-and-studies-ema-pdma-fda-approvals-mechanism-of-action-roa-nda-ind-and-companies]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/non-alcoholic-steatohepatitis-nash-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Nonalcoholic Steatohepatitis Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies here
News-ID: 3913497 • Views: …
More Releases from ABNewswire
Bedrock Restoration - Water Fire Mold Damage Service, Expands Water Damage Repai …
Water Fire Mold Damage Service, a trusted provider of property restoration, has announced expanded service offerings to meet the growing demand for professional water damage solutions in the region. Known for their reliable, customer-focused approach, the company continues to support both homeowners and businesses in recovering from unexpected property damage caused by water, fire, or mold.
Responding to a Growing Need for Water Damage Restoration
Property owners across Minnesota are increasingly seeking…
Winkler Kurtz LLP Expands Resources to Handle Increased Demand for Personal Inju …
For individuals searching for personal injury attorneys, the expansion of Winkler Kurtz LLP's team means greater accessibility and reduced wait times for consultations. The firm's deep roots in the Port Jefferson Station community allow them to understand local nuances, such as common accident hotspots and specific regional legal precedents.
Port Jefferson Station has seen a notable rise in personal injury cases, driven by factors such as increased traffic congestion, construction activity,…
Protecting Property Value: Hose Bros Inc Highlights How Professional Power Washi …
For residents searching for power washing near me, Hose Bros Inc offers accessible and reliable services tailored to the Millsboro community. Their local expertise ensures an understanding of regional challenges, such as the impact of salt air on coastal properties or the tendency for humidity to promote mold growth in shaded areas. This knowledge allows them to customize their approach, selecting appropriate pressure levels and cleaning agents for different surfaces.
In…
![Tampa Bay Home Remodeling Costs Guide [2025] Kitchen & Bathroom Renovation Prices](https://cdn.open-pr.com/9/1/914818326_g.jpg)
Tampa Bay Home Remodeling Costs Guide [2025] Kitchen & Bathroom Renovation Price …
A 2025 cost guide to kitchen, bathroom, and full home remodeling in Tampa Bay, featuring expert insights from Craftline Remodeling on pricing, budgeting, and contractor selection.
Market Overview: Understanding Tampa Bay Remodeling Investment Trends
Tampa Bay's home remodeling market has experienced significant cost evolution in 2025, with project expenses varying dramatically across South Tampa, Carrollwood, Seminole Heights, Clearwater, St. Petersburg, and Wesley Chapel based on material choices, project scope, and contractor expertise.…
More Releases for Nonalcoholic
Nonalcoholic Steatohepatitis (NASH) Market Massive Growth opportunity Ahead
Introduction
Nonalcoholic Steatohepatitis (NASH) is an advanced form of nonalcoholic fatty liver disease (NAFLD) characterized by fat accumulation in the liver along with inflammation and liver cell damage. If left untreated, NASH can progress to fibrosis, cirrhosis, liver failure, or hepatocellular carcinoma. Closely tied to the global obesity and diabetes epidemic, NASH has become a major healthcare burden, with millions affected worldwide and no widely approved curative therapy to date.
The NASH…
Drinking Nonalcoholic Beer Market Size 2024 to 2031.
Market Overview and Report Coverage
Drinking nonalcoholic beer is a type of beverage that has gained popularity as a healthier alternative to traditional beer. It contains little to no alcohol, making it suitable for individuals looking to enjoy the taste of beer without the effects of alcohol. The market for drinking nonalcoholic beer is steadily growing, with a projected CAGR of 6.00% during the forecasted period.
The future outlook of…
Nonalcoholic Steatohepatitis Treatment Market Analysis
As per the research conducted by GME, the Global Nonalcoholic Steatohepatitis Treatment Market will grow with a CAGR value of 39.1% by 2026. Over the forecast era, the production of NASH biomarkers is expected to be aided by increasing demand for non-invasive diagnostic tools and increased patient awareness. The low use of invasive procedures for disease diagnosis is due to the high cost of liver biopsy, its invasiveness, and patients'…
Nonalcoholic Steatohepatitis Therapeutics Market - Current status and future tre …
The global nonalcoholic steatohepatitis therapeutics market is dominated by companies such as Intercept Pharmaceuticals Inc., GENFIT SA, Galmed Pharmaceuticals Ltd., Zydus Cadila, AstraZeneca plc., Gilead Sciences, Inc., and Immuron Ltd. Key companies are focusing on the introduction of new drugs and therapeutics to treat nonalcoholic steatohepatitis (NASH). As per the Natural Medical Journal, the occurrence of nonalcoholic fatty liver diseases is expected to increase in the U.S., which is likely…
Emerging Opportunities in Nonalcoholic Steatohepatitis Therapeutics Market
Global Nonalcoholic Steatohepatitis (NASH) Market: Snapshot
Nonalcoholic Steatohepatitis (NASH), a syndrome found in non-alcoholic patients, causes damage to liver that is histologically akin to alcoholic hepatitis. NASH results from fat in the liver, along with inflammation. Symptoms in NASH usually do not show, but it can be severe and lead to cirrhosis, which is permanent damage to the liver.
Those suffering from obesity, dyslipidemia, and glucose intolerance are most likely…
Global Nonalcoholic Steatohepatitis Therapeutics Market
Nonalcoholic Steatohepatitis (NASH), also called the ‘silent disease,’ is a kind of fatty liver disease which typically affects people that are obese or diabetic. This disease is more prevalent in the younger generation and causes liver inflammation and/or damage owing to the accumulation of fat within the liver. The exact cause of this disease is still not clear; however, research activities are underway for finding effective treatments to cure this…
